Study on Epcoritamab for Patients with Relapsed or Refractory Large B Cell Lymphoma
- Substances:EpcoritamabLenalidomide+1
Spain- Participants:18–64 years · 65+ years
- Substances:Epcoritamab
- Sponsor:Fundacion Geltamo
Rare diseases
Investigational molecules
Locations
364 conditions with trials, the busiest first
1 206 trials across Europe, recruiting first
SpainStudy Comparing Zilovertamab Vedotin with Drug Combination for Untreated Patients with Diffuse Large B-Cell Lymphoma
BelgiumStudy of lisaftoclax combined with azacitidine for elderly patients with newly diagnosed acute myeloid leukemia
ItalyStudy on the Safety and Effectiveness of Emicizumab for Patients with TYPE 3 Von Willebrand Disease
BelgiumStudy of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients
BelgiumStudy on the Effectiveness and Safety of Human Normal Immunoglobulin (IV) for Adults with Chronic Immune Thrombocytopenia
CzechiaStudy of L-Annamycin and Cytarabine for Adults with Refractory or Relapsed Acute Myeloid Leukemia
BelgiumStudy on the Safety and Effects of Inobrodib, Betamethasone Sodium Phosphate, and Dimethyl Fumarate in Patients with Advanced Blood and Bone Marrow Cancers
SpainSafety Study of Sonrotoclax and Zanubrutinib for Patients with Untreated Chronic Lymphocytic Leukemia
FranceStudy on the Effectiveness and Safety of Sonrotoclax and Zanubrutinib for Adults with Relapsed or Refractory Mantle Cell Lymphoma
AustriaStudy on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
AustriaStudy on the Effectiveness of Lisaftoclax and Azacitidine in Adults with Newly Diagnosed Higher Risk Myelodysplastic Syndrome
BelgiumThe therapies tested most often in Blood and lymphatic system disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.